Abstract
The objectives of this study were to determine the effect of combination of methotrexate (MTX) and leflunomide (LEF) on type II collagen–induced arthritis rats and its mechanism. Curative effect was confirmed on CIA rats, which were randomized and divided into model, MTX, LEF and MTX + LEF group. Weights and joint swelling scores of rats were recorded. Interleukin (IL)-17, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) concentration in serum were determined by ELISA. H&E dyeing of joint was used to estimate the inflammation and osteoclasia extent. The mechanism was investigated through fibroblast-like synoviocytes isolated from RA patients. The effect of MTX and LEF on cell viability, and RANKL and OPG expression were indicated through MTT and RT-PCR analysis, respectively. Combination therapy would be effective in treating CIA rats. Joint swelling scores and IL-17 and RANKL level in serum were decreased obviously (P < 0.05), while OPG level was elevated (P < 0.05). Anti-inflammatory and anti-osteoclasia effect would be indicated by H&E dyeing results. Moreover, FLS cell viability was inhibited by combination treatment in vitro (P < 0.05), and expression of osteoclasia-related genes (RANKL and OPG) was modified (P < 0.05). Combination therapy would relive the synovium hypertrophy through depressing cell viability and osteoclasia through decreasing RANKL and increasing OPG expression. Otherwise, combination was superior to monotherapy.
Similar content being viewed by others
References
Smolen JS, Steiner G (2003) Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2:473–488
Gaffo A, Saag KG, Curtis JR (2006) Treatment of rheumatoid arthritis. Am J Health Syst Pharm 63:2451–2465
Rachapalli SM, Williams R, Walsh DA et al (2010) First-line DMARD choice in early rheumatoid arthritis—do prognostic factors play a role? Rheumatology (Oxford) 49:1267–1271
Caramaschi P, Bambara LM, Pieropan S et al (2009) Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. Joint Bone Spine 76:333–342
Christensen R, Kristensen LE, Geborek P et al (2009) The efficacy of the three available anti-tumour necrosis factor therapies in patients with rheumatoid arthritis: a meta-analytic literature review–secondary publication. Ugeskr Laeger 171:2192–2194
Feher J, Lengyel G (2009) Effectiveness and safety of biological therapy with adalimumab. Orv Hetil 150:1215–1222
Nasonov EL (2009) Rituximab treatment of rheumatoid arthritis: new evidence. Ter Arkh 81:82–91
Quartuccio L, Lombardi S, Fabris M et al (2009) Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects. Ann NY Acad Sci 1173:692–700
Wiens A, Correr CJ, Pontarolo R et al (2009) A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol 70:337–344
Falgarone G, Semerano L, Rulle S, Boissier MC (2009) Targeting lymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine 76:327–332
Bracewell C, Isaacs JD, Emery P, Ng WF (2009) Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. Expert Opin Biol Ther 9:909–919
Muhammad K, Roll P, Seibold T et al (2011) Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in preswitch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis 70:1507–1510
Martinez JA, Loza E, Carmona L (2009) Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). Clin Exp Rheumatol 27:678–684
Smolen JS, Aletaha D, Machold KP (2005) Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19:163–177
Kalb RE, Strober B, Weinstein G et al (2009) Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 60:824–837
Schroder O, Stein J (2003) Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 98:530–537
Ochaion A, Bar-Yehuda S, Cohn S et al (2006) Methotrexate enhances the anti-inflammatory effect of CF101 via up- regulation of the A3 adenosine receptor expression. Arthritis Res Ther 8:R169
Hasko G, Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. Trends Immunol 25:33–39
Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action of leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208
Katchamart W, Trudeau J, Phumethum V et al (2009) Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 68:1105–1112
Kremer JM (1999) Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:24–26
Wessels JAM, Huizinga TWJ, Guchelaar H-J (2008) Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology 47:249–255
Cook AD, Braine EL, Campbell IK et al (2001) Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 3:293–298
Pagat GE, Barnes JM (1964) Interspecies Dosage Conversion Scheme in Evaluation of Results and Quantitative Application in Different Species. In: Laurence DR, Bacarach AL (eds) Evaluation of drug activities: pharmacometrics. Academic press, London
Urakawa K, Mihara M, Suzuki T et al (2000) Polyglutamation of antifolates is not required for induction of extracellular release of adenosine or expression of their anti-inflammatory effects. Immunopharmacology 48:137–144
Lee YA, Kim JY, Hong SJ et al (2007) Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients. Clin Rheumatol 26:2023–2029
Mor A, Abramson SB, Pillinger MH (2005) The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin Immunol 115:118–128
David AF Alison G, Rachel M et al Lundy (2010) Cell-cell Interactions in Rheumatoid Arthritis Synovium Rheum Dis Clin N Am 36: 311–323
Weiwei F, Weimin L, Wei L et al (2009) IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 87:212–218
Cho ML, Jung YO, Kim KW et al (2008) IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp Mol Med 40:237–245
Katz Y, Nadiv O, Beer Y (2001) Interleukin-17 enhances tumor necrosis factor α-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts. Arthritis Rheum 44:2176–2184
Irena L, Daphna P, David L et al (2006) The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. Cytokine 33:106–110
Kraan MC, Smeets TJ, van Loon MJ et al (2004) Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 63:1056–1061
Masataka A, Hiroshi T (2007) The molecular understanding of osteoclast differentiation. Bone 40:251–264
Sonja H, Gerhard K, Georg S (2008) Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol Med 14:245–253
Wada T, Nakashima T, Hiroshi N et al (2006) RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 12:17–25
Nicola G, Simona C, Vittorio R (2004) New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-κB ligand (RANKL). Exp Hematol 32:685–691
Toru Y, Yuki N, Naomi I et al (2009) IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-a antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem 108:947–955
Zhang F, Tanaka H, Kawato T et al (2011) Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie 93:296–305
Ju JH, ChoML JhunJY et al (2008) Oral administration of type-II collagen suppresses IL-17 associated RANKL expression of CD4+T cells in collagen-induced arthritis. Immunol Lett 117:16–25
Schett G, Middleton S, Bolon B (2005) Additive bone protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 52:1604–1611
Acknowledgments
We would like to thank Nanjing Municipal Health Bureau in China (project number: ZKX08022, YKK11101) for providing funds to carry out the program.
Conflict of interest
All the authors declared that there was no conflict of interest in this paper.
Author information
Authors and Affiliations
Corresponding author
Additional information
Both Yao Yao and Cong-zhu Ding are the first authors because of their equal effort for the study.
Rights and permissions
About this article
Cite this article
Yao, Y., Ding, Cz. & Fang, Y. Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats. Rheumatol Int 33, 1845–1853 (2013). https://doi.org/10.1007/s00296-013-2674-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-013-2674-7